deltatrials
Completed NA INTERVENTIONAL 1-arm NCT01066403

Adjuvant Therapy With Pergolide in Treating Cognitive Deficits in Schizophrenia

Dopaminergic Modulation of Prefrontal Functions in Schizophrenic Patients: Adjuvant Therapy With Pergolide

Sponsor: Heidelberg University

Conditions Schizophrenia
Interventions Pergolide
Updated 4 times since 2017 Last updated: Feb 9, 2010 Started: Oct 31, 2003 Primary completion: Mar 31, 2008 Completion: Mar 31, 2008
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01066403, this NA trial focuses on Schizophrenia and remains completed. Sponsored by Heidelberg University, it has been updated 4 times since 2003, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.

Status Flow

~Jan 2017 – ~Jan 2021 · 48 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 22 months · monthly snapshotCompleted

Change History

4 versions recorded
  1. Sep 2024 — Present [monthly]

    Completed NA

  2. Jul 2024 — Sep 2024 [monthly]

    Completed NA

  3. Jan 2021 — Jul 2024 [monthly]

    Completed NA

  4. Jan 2017 — Jan 2021 [monthly]

    Completed NA

    First recorded

Oct 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Heidelberg University
  • Stanley Medical Research Institute
Data source: Heidelberg University

For direct contact, visit the study record on ClinicalTrials.gov .